EYLEA Injection gets approval in Japan for treatment of macular edema...
Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has received approval for the treatment of Macular Edema Following Central Retinal Vein Occlusion from the Japanese...
View ArticleNEXAVAR tablets receive FDA approval for treatment of patients with thyroid...
Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral...
View ArticleStudy reveals new mechanism that may block formation of new blood vessels and...
A study led by researchers at Boston University School of Medicine demonstrates a new mechanism involving a signaling protein and its receptor that may block the formation of new blood vessels and...
View ArticleFour-drug regimen shows first-line efficacy in advanced NSCLC
A four-drug combination of cetuximab, bevacizumab, carboplatin, and paclitaxel is effective and has acceptable safety as a first-line treatment for advanced non-small-cell lung cancer, US researchers...
View ArticleDiscovery could lead to new way to combat cancer
One way to defeat an opponent is to cut off its supply lines. Tumors are no different. The supply lines for tumors are the blood vessels that ferry oxygen and nutrients to the cells. Restricting the...
View ArticleNew drug combination therapy effective for patients with HER2-positive breast...
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast...
View ArticleCombination of ramucirumab and docetaxel fails to delay advanced breast...
Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a...
View ArticleBioLineRx reports promising initial results from Phase 2 trial of BL-8040 in...
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today promising initial results for its BL-8040...
View ArticleFDA accepts Regeneron's EYLEA Injection sBLA for standard review
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA...
View ArticleStudy finds milk serves as protective carrier of bioactive molecules
Polyphenols found in tea manifest anti-cancer effects but their use is limited by poor bioavailability and disagreeable taste. A new study in the Journal of Dairy Science- finds that when...
View ArticleMelanocyte-secreted fibromodulin promotes angiogenic microenvironment
The decreased vision loss that accompanies age-related macular degeneration (AMD) is associated with abnormal blood vessel growth in the eye. Frequencies of AMD development are different among racial...
View ArticleHypoxic preconditioning has protective effects against acute cerebral infarction
Hypoxic preconditioning has been shown to have protective effects against acute cerebral infarction. To investigate the protective mechanisms of hypoxic preconditioning in relation to its effects on...
View ArticleNew study highlights the importance of beta3-integrin protein in cancer research
A protein that has been at the centre of cancer drug design for the last 20 years should not be given up on according to new research from the University of East Anglia (UEA).
View ArticleNew study gives hope for novel glioblastoma multiforme treatment
A new study is giving researchers hope that novel targeted therapies can be developed for glioblastoma multiforme, the most common and most aggressive form of brain cancer, after demonstrating for the...
View ArticleSynta initiates three multicenter trials to evaluate ganetespib with...
Synta Pharmaceuticals Corp. today announced the initiation of three multicenter, randomized trials supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, evaluating ganetespib...
View ArticleStudy shows high-fiber diet reduces risk of colon problems
Scientists have more reasons for you to eat fiber and not abuse antibiotics.
View ArticleBreakthrough technology could provide new approach for treatment of chronic...
A team of researchers led by an NIBIB grantee at Vanderbilt University has created a biodegradable scaffold that enables sustained, local delivery of gene-silencing factors called siRNA to promote...
View ArticleBioLineRx's BL-8040 gets FDA Orphan Drug Designation for stem cell...
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has received notice from the U.S....
View ArticleStudy shows melatonin hormone may inhibit tumor growth and cell production
An early stage study shows melatonin - a hormone that regulates the body's sleep and awake cycles - may have the potential to help slow the growth of certain breast cancer tumors, according to...
View ArticleFindings explain molecular mechanisms underlying microvascular disease in...
Patients with diabetes are at increased risk of microvascular complications, which develop when the body's small blood vessels become diseased. One of the most common problems results when wounds fail...
View Article
